The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor interventionSusan K. Peirce(Emory University), Donald L. Durden(UC San Diego Health System)Cancer Chemotherapy and PharmacologyOctober 23, 201010.1007/s00280-010-1486-7Cited by 38SaveCiteExport RISWatch citationsRelated PapersPI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma|PLoS ONE|2016|31